541-P: Patterns of Physical Activity and Cardiometabolic Risk in Hispanic/Latino Adults with or Vulnerable to Type 2 Diabetes

While physical activity (PA) improves physical health, and wearable accelerometers clarify PA behavior, patterns of PA and cardiometabolic risk have not been well studied in ethnic minorities. In the Mil Familias observational cohort study of Hispanic/Latino adults with or at risk for type 2 diabetes (T2D) , PA was measured in 118 women and 59 men (age 56.9±10.6 years, mean±SD, HbA1c 7.1 [6.3, 9.2] %, median [IQR]) ; 150 had T2D (duration 12.2±8.2 years) . An ActiGraph wGT3X-BT was worn on the right hip 24 hours/day for 7 consecutive days (mean 4.5±1.8 days) with ≥hours waking wear time as a valid day. We found that study participants in the low HbA1c (<7.0%) had significantly less waking sedentary minutes (SED) per day than those with high (≥7.0%) HbA1c (see table) . For men, there were significant differences for time standing and sitting, levels of moderate to vigorous physical activity (MVPA) , and LDL cholesterol. In women with diabetes (n=103) , individual fasting HDL (50.7±11.7 mg/dL) was positively correlated with light physical activity minutes (266.0±66.8, r=0.3, p<0.05) . Also, sitting minutes (328±83.2) and standing minutes (352±97.4) correlated with waist circumference (100±12.9 cm) , r=0.2 & r=-0.2, p≤0.respectively. In these Hispanic/Latino adults, PA (from work and/or exercise) and SED time appear to have important cardiometabolic health implications. Disclosure W.C.Bevier: Research Support; Abbott Diabetes. S.Lamunion: None. M.Roach: None. N.M.Glantz: Research Support; Abbott. A.Larez: Research Support; Abbott. K.N.Castorino: Consultant; Lilly Diabetes, Research Support; Abbott Diabetes, Dexcom, Inc., Drawbridge Health, Inc., Eyenuk, Inc., Laxmi Therapeutic Devices, Medtronic, National Institute of Diabetes and Digestive and Kidney Diseases, Novo Nordisk, Speaker's Bureau; Dexcom, Inc. K.Y.Chen: None. D.Kerr: Advisory Panel; Abbott Diabetes, Novo Nordisk A/S, Sanofi, Consultant; Evidation Health, Research Support; Novo Nordisk A/S, Stock/Shareholder; Glooko, Inc., Hi.Health.